Ketek is a drug owned by Sanofi Aventis Us Llc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 01, 2018. Details of Ketek's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5635485 | Erythromycin compounds |
Apr, 2018
(7 years ago) |
Expired
|
| USD459798 | Pill tablet |
Sep, 2015
(10 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Ketek's patents.
Latest Legal Activities on Ketek's Patents
Given below is the list of recent legal activities going on the following patents of Ketek.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 02 Jul, 2002 | USD459798 |
| Issue Notification Mailed | 13 Jun, 2002 | USD459798 |
| Receipt into Pubs | 31 May, 2002 | USD459798 |
| Workflow - File Sent to Contractor | 26 Apr, 2002 | USD459798 |
| Application Is Considered Ready for Issue | 22 Apr, 2002 | USD459798 |
| Issue Fee Payment Received | 15 Apr, 2002 | USD459798 |
| Workflow -Received 85b - Unmatched | 15 Apr, 2002 | USD459798 |
| Issue Fee Payment Verified | 15 Apr, 2002 | USD459798 |
| Workflow - Drawings Finished | 18 Mar, 2002 | USD459798 |
| Mail Formal Drawings Required | 04 Feb, 2002 | USD459798 |
US patents provide insights into the exclusivity only within the United States, but
Ketek is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Ketek's family patents as well as insights into
ongoing legal events
on those patents.
Ketek's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Ketek's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 01, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Ketek Generics:
There are no approved generic versions for Ketek as of now.
Alternative Brands for Ketek
Ketek which is used for treating respiratory infections caused by susceptible strains of designated microorganisms in adults over 18 years old., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Burke Therap |
| |||
About Ketek
Ketek is a drug owned by Sanofi Aventis Us Llc. It is used for treating respiratory infections caused by susceptible strains of designated microorganisms in adults over 18 years old. Ketek uses Telithromycin as an active ingredient. Ketek was launched by Sanofi in 2005.
Approval Date:
Ketek was approved by FDA for market use on 09 February, 2005.
Active Ingredient:
Ketek uses Telithromycin as the active ingredient. Check out other Drugs and Companies using Telithromycin ingredient
Treatment:
Ketek is used for treating respiratory infections caused by susceptible strains of designated microorganisms in adults over 18 years old.
Dosage:
Ketek is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 400MG | TABLET | Discontinued | ORAL |
| 300MG | TABLET | Discontinued | ORAL |